Literature DB >> 27474103

A tumor profile in Edwards syndrome (trisomy 18).

Daniel Satgé1, Motoi Nishi, Nicolas Sirvent, Michel Vekemans.   

Abstract

Constitutional trisomy 18 causes Edwards syndrome, which is characterized by intellectual disability and a particular set of malformations. Although this condition carries high mortality during prenatal and early postnatal life, some of the rare infants who survive the first months develop benign and malignant tumors. To determine the tumor profile associated with Edwards syndrome, we performed a systematic review of the literature. This review reveals a tumor profile differing from those of Down (trisomy 21) and Patau (trisomy 13) syndromes. The literature covers 45 malignancies: 29 were liver cancers, mainly hepatoblastomas found in Japanese females; 13 were kidney tumors, predominantly nephroblastomas; 1 was neuroblastoma; 1 was a Hodgkin disease; and 1 was acute myeloid leukemia in an infant with both trisomy 18 and type 1 neurofibromatosis. No instances of the most frequent malignancies of early life-cerebral tumors, germ cell tumors, or leukemia--are reported in children with pure trisomy 18. Tumor occurrence does not appear to correlate with body weight, tissue growth, or cancer genes mapping to chromosome 18. Importantly, the most recent clinical histories report successful treatment; this raises ethical concerns about cancer treatment in infants with Edwards syndrome. In conclusion, knowledge of the Edwards' syndrome tumor profile will enable better clinical surveillance in at-risk organs (i.e., liver, kidney). This knowledge also provides clues to understanding oncogenesis, including the probably reduced frequency of some neoplasms in infants and children with this genetic condition.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Edwards syndrome; cancer; cancer protection; hepatoblastoma; nephroblastoma; trisomy 18

Mesh:

Year:  2016        PMID: 27474103     DOI: 10.1002/ajmg.c.31511

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  6 in total

Review 1.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

Review 2.  The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System.

Authors:  Daniel Satgé; Markus G Seidel
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

Review 3.  Future Perspectives in Oxidative Stress in Trisomy 13 and 18 Evaluation.

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Ahsan Hameed; Adam Jacek Krętowski; Monika Zbucka-Krętowska
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

Review 4.  Hepatoblastoma in molecularly defined, congenital diseases.

Authors:  Gunther Nussbaumer; Martin Benesch
Journal:  Am J Med Genet A       Date:  2022-04-28       Impact factor: 2.578

5.  Single-cell chromatin accessibility landscape of human umbilical cord blood in trisomy 18 syndrome.

Authors:  Xiaofen Qiu; Haiyan Yu; Hongwei Wu; Zhiyang Hu; Jun Zhou; Hua Lin; Wen Xue; Wanxia Cai; Jiejing Chen; Qiang Yan; Weier Dai; Ming Yang; Donge Tang; Yong Dai
Journal:  Hum Genomics       Date:  2021-06-30       Impact factor: 4.639

Review 6.  Integrating the DNA damage and protein stress responses during cancer development and treatment.

Authors:  Vassilis G Gorgoulis; Dafni-Eleftheria Pefani; Ioannis S Pateras; Ioannis P Trougakos
Journal:  J Pathol       Date:  2018-07-19       Impact factor: 7.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.